Physician profile
Myanandi Than
NPI 1356426522
$1,257.82
in general payments reported to CMS, 2019-2025
12 companies · $282 in 2025
The $282 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.76 · 2020: $29.72 · 2021: $26.02 · 2022: $69.12 · 2023: $159 · 2024: $650 · 2025: $282.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,068 · Education: $23.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,068.16 |
| Education | $23.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $294.60 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $188.45 | 2024-2025 | Nucala, Shingrix, Arexvy |
| Pfizer INC. | $166.06 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $132.23 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $119.34 | 2023-2025 | Eliquis, Camzyos |
| Organon LLC | $93.25 | 2024 | |
| Lilly USA, LLC | $65.79 | 2024 | Mounjaro, Zepbound, Jardiance |
| Viiv Healthcare Company | $65.62 | 2023-2024 | Dovato |
| Xeris Pharmaceuticals, INC. | $51.96 | 2024-2025 | Gvoke Hypopen |
| Genzyme Corporation | $28.56 | 2025 | |
| Amgen INC. | $28.36 | 2024 | Evenity, Prolia |
| Allergan, INC. | $23.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myanandi Than listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.